Benefits
Diabetes Trial Claim With No Citation On This Page
This page previously reported a 24-week trial of 250 mg/day in 110 people with type 2 diabetes, with specific figures for fasting glucose, HbA1c, insulin and HOMA-IR. That trial is not among the five references listed here, so none of those numbers can be checked against a source and they should not be relied on. Type 2 diabetes is a diagnosed disease, a dietary supplement is not a treatment for it, and blood sugar management belongs with a physician.
Cardiovascular Health
The cholesterol claim previously made here does not survive the meta-analysis this page cites. Pooling 15 randomized trials of tocotrienols across 20 arms, total cholesterol did not change significantly (+0.010 mmol/L) and LDL cholesterol did not change significantly either (+0.095 mmol/L). Note the signs: both moved numerically upward, not down. Triglycerides were also not significant overall (-0.112 mmol/L) and fell significantly only in arms using 200 mg/day or more (-0.177 mmol/L). The one lipid that did move was HDL cholesterol, up 0.146 mmol/L. That analysis covers tocotrienols generally, not annatto DeltaGold specifically.
Comparative Potency Claim (Uncited)
No study cited on this page compared delta- or gamma-tocotrienol against alpha forms for any metabolic outcome, and the phrase established in multiple studies pointed to nothing a reader could check. Treat the comparative potency claim as unsupported here.
Bone Turnover Markers in Postmenopausal Osteopenic Women
This is the only annatto-specific evidence on the page. In 89 postmenopausal osteopenic women, 87 of whom completed, taking 430 or 860 mg/day of the annatto extract for 12 weeks, urinary NTX fell, soluble RANKL and the sRANKL/OPG ratio fell, the BALP/NTX ratio rose, and urinary 8-OHdG fell. Serum OPG and urinary calcium did not change. These are bone turnover and oxidative stress markers measured over 12 weeks. Neither bone mineral density nor fracture outcomes were measured, and the companion report from the same cohort found no significant differences in the other outcomes it assessed.
Tocopherol-free Distinction
Alpha-tocopherol has been reported to interfere with tocotrienol uptake, and DeltaGold contains no tocopherols. Note the tension this creates on this page. Two of the five references are the very sources this argument disqualifies: the 2002 lipid trial used a rice bran tocotrienol-rich fraction, and the 2013 liver trial used mixed palm tocotrienols. If tocopherol content makes those preparations a poor guide to what DeltaGold does, their results cannot also be counted as evidence for it. The page cannot have this both ways.
GRAS Food Status (Regulatory, Not a Health Benefit)
FDA does not grant, award or confer GRAS status. A company either self-affirms that an ingredient is generally recognized as safe or files a GRAS notice, to which FDA may respond with a letter stating it has no questions. That is a genuine regulatory step and it does support use in foods and beverages, but it is a safety determination about a food use, not evidence that the ingredient does anything.
Manufacturing Note (Not a Health Benefit)
Patented process and US-based production. This describes how and where the ingredient is made. It is a manufacturing and supply detail, not a health benefit, and says nothing about what the ingredient does in the body.
Triglycerides: What the Cited Evidence Shows
The 10.3 percent versus 0.9 percent figures came from the diabetes trial that is not cited on this page, so they cannot be verified. In the meta-analysis this page does cite, triglycerides did not fall significantly overall (-0.112 mmol/L). A significant reduction appeared only in the subset of arms dosing 200 mg/day or more (-0.177 mmol/L).
Mechanism of action
Delta- and Gamma-Tocotrienol Activity
Delta-tocotrienol has a less methylated chromanol ring than the alpha form, and all tocotrienols carry an unsaturated side chain. Both features are proposed to affect how these molecules sit in cell membranes. That is structural reasoning, not a measured outcome. No human study cited on this page compared delta-tocotrienol against alpha forms, so superiority in metabolic applications is not something this page can support.
HMG-CoA Reductase Modulation
Tocotrienols suppress HMG-CoA reductase, the same enzyme statins inhibit, though by a different route. This is a laboratory mechanism. In the pooled human data cited here, total and LDL cholesterol did not change significantly, so the mechanism should not be read as a demonstrated cholesterol-lowering effect in people.
miRNA Modulation (T2DM Trial)
The microRNA figures previously quoted here came from the diabetes trial that is not among this page's references, so they cannot be verified. No study cited on this page measured microRNA.
NF-kB Anti-Inflammatory
Delta- and gamma-tocotrienol have been shown in laboratory work to modulate the NF-kB pathway. The IL-6 and TNF-alpha percentages previously listed here came from the uncited diabetes trial. No reference on this page reports either marker.
Antioxidant Activity
The unsaturated side chain is thought to help tocotrienols distribute into tissue membranes. In the 12-week postmenopausal osteopenic cohort, urinary 8-OHdG, a marker of oxidative DNA damage, fell relative to placebo. Broader claims that tocotrienols out-scavenge tocopherols are not established by anything cited here.
No Interference from Alpha-Tocopherol
DeltaGold's tocopherol-free composition prevents alpha-tocopherol's interference with tocotrienol uptake and function.
Clinical trials
UNCITED. A 24-week trial of 250 mg/day in 110 people with type 2 diabetes was described here, but it is not among the five references on this page and no source is given for it.
Reported as 110 people with type 2 diabetes. Not verifiable from any reference on this page.
No verifiable findings. The figures previously listed here for fasting glucose, HbA1c, insulin, HOMA-IR, triglycerides, LDL, IL-6, TNF-alpha and microRNA have no source on this page. Type 2 diabetes is a disease and this ingredient is not a treatment for it.
12-week randomized double-blind placebo-controlled trial of annatto-derived tocotrienol at 90 percent delta and 10 percent gamma, 430 or 860 mg/day, reported in Osteoporos Int 2018 (PMID 29330573), with a companion safety and quality-of-life paper from the same cohort naming DeltaGold 70 (PMID 29954374).
89 postmenopausal osteopenic women enrolled, 87 completed.
Urinary NTX, soluble RANKL, the sRANKL/OPG ratio and urinary 8-OHdG fell, and the BALP/NTX ratio rose. Serum OPG and urinary calcium did not change. These are bone turnover and oxidative stress markers, not bone mineral density and not fractures, neither of which was measured. The companion paper from the same cohort found no effect on liver or kidney function and no significant differences in the other outcomes it measured, including quality of life, body composition, physical activity and nutrient intake. Serum delta-tocotrienol did rise, confirming absorption.
Meta-analysis of 15 randomized controlled trials across 20 arms on tocotrienol supplementation and lipid profile, Complement Ther Med 2020 (PMID 32951713). This replaces an earlier card that referred only to multiple DeltaGold trials with no citation at all.
Pooled participants from 15 randomized trials of tocotrienol supplementation, not annatto DeltaGold specifically.
HDL cholesterol rose 0.146 mmol/L, the only significant lipid change. Total cholesterol (+0.010 mmol/L) and LDL cholesterol (+0.095 mmol/L) were not significant and moved numerically upward. Triglycerides (-0.112 mmol/L) were not significant overall and reached significance only in arms using at least 200 mg/day (-0.177 mmol/L). This analysis did not report inflammatory biomarkers.